Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses RNA Stabilization Technology to Celera

NEW YORK, Sept. 6-Ambion's diagnostics division has licensed its RNA stabilization technology to Celera Diagnostics, the company said today.

 

Through the deal, Celera gets nonexclusive worldwide rights to the technology, which it will use to develop molecular diagnostic assays. Ambion will also manufacture custom reagents for Celera.

 

Ambion's Armored RNA technology, a system jointly developed by Ambion and Centron, protects RNA by packaging it in bacteriophage coat proteins. The technique is useful in producing long-lasting, stable RNA controls for assays.

 

Celera Diagnostics is a joint venture between Celera Genomics and Applied Biosystems.

 

Ambion RNA Diagnostics is a division of Ambion, a RNA-focused tools company based in Austin, Texas.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.